NCT02342704
Who may be able to join
Who might be able to join this trial:
For people with Multiple Sclerosis (MS):
- You must have a confirmed diagnosis of relapsing MS, with a disability score between 0.0 and 5.5 on a standard MS scale.
- If you are currently taking one of these MS medications (Betaseron, Rebif, Avonex, Copaxone, Extavia, Tecfidera, or Aubagio), you must have been on it for at least 6 months, have at least 9 lesions visible on a brain MRI, and have had at least 1 relapse in the last 6 months along with new lesions shown on a recent brain MRI (confirm with trial site).
- If you have a very active form of MS (whether or not you have taken any MS medication before), you must have had at least 2 severe relapses in the past 12 months and have new lesions visible on a recent brain MRI (confirm with trial site).
For healthy volunteers:
- You must be in generally good health, with no history of serious illnesses, confirmed by a physical exam and medical history.
- If you are able to become pregnant, you must be willing and able to use effective birth control for the entire duration of the study.
- You must not have had any drug or alcohol misuse problems in the past year.
Who may not be able to join:
For people with Multiple Sclerosis (MS):
- You have been diagnosed with Primary Progressive MS or Secondary Progressive MS.
- You have HIV, hepatitis C, or an active hepatitis B infection, or test positive for these at screening.
- You have previously been treated with the MS medications natalizumab or fingolimod.
- You have a current or past history of cancer, including blood cancers or solid tumours (except certain completely removed and cured skin cancers).
- You have a history of serious opportunistic infections or other significant major illnesses, as judged by the study doctor.
- You have had a significant infectious illness (such as pneumonia or blood poisoning) within the past month.
- You have had problems with drug or alcohol misuse in the past year.
- You have used certain immune-suppressing medications or received certain biological treatments within the past 12 months (confirm with trial site for the full list).
- You have had a heart attack, unstable chest pain, stroke, mini-stroke, or severe heart failure in the past 6 months.
- You are currently taking certain heart rhythm medications known as Class Ia or Class III anti-arrhythmic drugs (confirm with trial site for specific drug names).
- You are currently taking medications that slow your heart rate, such as certain blood pressure or heart medications (confirm with trial site for specific drug names).
- You have high blood pressure that is not controlled by your current medications.
- You have a history of severe lung disease, lung scarring, or severe chronic obstructive pulmonary disease (COPD).
- You have received a live vaccine within the 8 weeks before screening.
For healthy volunteers:
- You experience claustrophobia (fear of enclosed spaces) severe enough to prevent you from having a reliable MRI scan.
- You have a history of major illness, including neurological conditions, as determined by the study doctor.
- You have a metal implant or device in your body that is affected by MRI, such as a pacemaker, aneurysm clip, or implanted defibrillator, or any metal fragments in your body.
- You are currently pregnant, breastfeeding, or have a positive pregnancy test at screening.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Cumulative Number of ≥ 6-Month Confirmed T1-Hypointense Lesions Arising From New On-Treatment T1-Gadolinium-Enhancing (Gd+) Lesions
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.